Analyst Ratings for Silver Standard Resources Inc. (SSRI)

Updated: 2017-07-27

Silver Standard Resources Inc. (NASDAQ:SSRI) was awarded an average rating of Overweight from investment analysts following the stock. About 30 days ago, SSRI was issued an average rating of Overweight.

Of the 10 analysts covering the stock, 5 gave it a buy rating, 1 issued an overweight rating, 4 issued a hold rating, 0 issued an underweight rating, and 0 issued a sell rating. Over the past 90 days, the number of analysts that are bullish on the stock has increased by 1. During this time, the number of analysts bearish on the stock has increased by 0.

Many analysts weighed in on price targets for SSRI. The maximum price target given was 17.26, implying a possible profit of 80.53 percent. The most pessimistic analyst gave a price target of 10.56, implying a possible loss of 10.45 percent. Note that investment analysts can be biased in their reporting on companies's ratings and price targets.

In the last 30 days, analysts have changed their quarterly earnings estimates downwards by an average of -0.89 percent. That number becomes 0 percent if we expand the time horizon to include the past 3 months instead of just one. On the other hand, earnings estimates for the fiscal year have been revised downwards by -12.57 percent, as compared to a month ago. Expanding the time horizon to 3 months, the average change in fiscal year estimates becomes 0 percent.

People are often interested in whether analysts were united in the direction of their revisions. 0 analysts have revised their quarterly estimates upwards in the past 30 days, while 2 analysts made negative revisions. Also over the last month, 0 analysts increased their estimates for the FY earnings, compared to 2 analysts that revised their FY estimates downwards.

The growth rate of SSRI's earnings is estimated by analysts to be -53.99 percent. Another measure frequently examined by investors is the PEG ratio. Smaller PEG ratios are desirable, as that can indicate whether the high price level of a stock is warranted by high growth. Many investors consider PEG ratios between 0 and 1 as preferrable, although it is frequently more appropriate to compare PEG ratios to the company's peers. SSRI has a PEG ratio of -0.27.

SSRI has a 52-week high of 15.84 and a 52-week low of 7.70. Today's price is 24.17 percent above the 52-week low, and 39.64 percent lower than its 52-week high. SSRI has a P/E ratio of 14.59. Investors typically compare the P/E ratio to a company's peers in the industry. The SSRI value stock report compares SSRI to some of its peers using value stock charts. The market cap of SSRI is $1.17 billion. SSRI will post this quarters earnings in days, on 0000-00-00.